A novel antiviral protein, designated as Stellarmedin A, was purified from Stellaria media (L.) Vill. (Caryophyllaceae) by using ammonium sulfate precipitation, cation-exchange chromatography system. Gel electrophoresis analysis showed that Stellarmedin A is a highly basic glycoprotein with a molecular weight of 35.1 kDa and an isoelectric point of ∼8.7. The Nterminal 14-amino acid sequence, MGNTGVLTGERNDR, is similar to those of other plant peroxidases. This protein inhibited herpes simplex virus type 2 (HSV-2) replication in vitro with an IC 50 of 13.18 mg/ml and a therapeutic index exceeding 75.9. It was demonstrated that Stellarmedin A affects the initial stage of HSV-2 infection and is able to inhibit the proliferation of promyelocytic leukemia HL-60 and colon carcinoma LoVo cells with an IC 50 of 9.09 and 12.32 mM, respectively. Moreover, Stellarmedin A has a peroxidase activity of 36.6 mmol/min/mg protein, when guaiacol was used as substrate. To our knowledge, this is the first report about an anti-HSV-2 protein with antiproliferative and peroxidase activities from S. media.
Introduction
Herpes simplex virus (HSV) is a DNA-containing enveloped virus, which brings commonly viral infections in humans causing a variety of diseases. HSV-1 and HSV-2 can be distinguished on the basis of clinical manifestations and biochemical and serological characteristics. Generally, HSV infection is benign or asymptomatic in immune-competent individuals. However, in patients with an immature or weak immune system, such infections can be serious and even life-threatening [1, 2] . The major antiviral therapy for HSV infection involves the use of nucleoside analogues, such as acyclovir. However, the increasing clinical use of this type of antiviral agents has been linked with the emergence of drug-resistant herpes virus strains [3] [4] [5] . Therefore, the development of anti-HSV agents with different modes of action is required.
The study of medicinal plants can lead to the identification of novel bioactive plant compounds which are suitable for drug discovery and development. Recently, research on herbs prescribed in traditional Chinese medicine (TCM) has attracted great attention as many have shown numerous biological activities including anti-HSV capability [6] [7] [8] [9] , and a number of anti-HSV proteins derived from herbs have been described [10] [11] [12] .
Stellaria media (L.) Vill. (Caryophyllaceae) is a known invasive weed which disturbs grounds in the world. As one of the traditional medicinal plants, this plant has been used for hundreds of years in Chinese community, and shows very effective anti-inflammatory and antiviral activities [13] . In both Europe and North America, its herbal use also has a very long history, especially in the external treatment of skin itching [14] . However, not all of these uses are supported by scientific evidence; only those using phenolic acids, flavones [15, 16] , lipid [17] , oligosaccharides [18] , and cyclic dipeptides [19] have been reported. The composition of the effective constituents in this plant has not been adequately studied.
It has been reported that the extract of S. media is very useful for the treatment of HSV and is widely used in the eastern and southern regions of China. In this study, a series of experiments were conducted to investigate the anti-HSV-1 and anti-HSV-2 activity of S. media in vitro. A novel protein, designated as Stellarmedin A, was found to process anti-HSV-2 activity as well as strong antiproliferative and peroxidase activities. Our findings suggest that Stellarmedin A might have potential applications in agriculture and in medicine.
Prof. Changqi Yuan (Institute of Botany, Nanjing, China). The validated specimen was kept in a herbarium. The human cancer cell lines, HL-60 (promyelocytic leukemia) and LoVo (colon carcinoma), were purchased from the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). Human normal cell line, human fibroblast (HFB) was provided by the Pennsylvania State University College of Medicine and Milton S. Hershey Medical Center (Hershey, USA). Carboxymethyl (CM) Sepharose and Sephadex 75 10/300 GL columns were purchased from GE Healthcare (Fairfield, USA). Dulbecco's modified Eagle's medium (DMEM) was purchased from Life Technology (Grand Island, USA). 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) was from Sigma Chemical (St Louis, USA). The HSV-1 and HSV-2 strains and Vero cells were provided by the Dermatosis Research Center, China Medical Academy of Science (Nanjing, China).
Preparation of S. media extracts
The whole plants were rinsed, chopped, and homogenized in three volumes of extraction buffer [50 mM Tris-Cl, pH 6.8, containing 0.2 M NaCl, 10 mM ascorbic acid, 1 mM phenylmethylsulfonyl fluoride, and 1% (w/v) polyvinylpyrrolidone]. The homogenate was stirred for 12 h and centrifuged at 8000 Â g for 20 min. The supernatant (fraction 1) was lyophilized and resuspended in deionized water (final concentration of 20 mg/ml). Ammonium sulfate was slowly added to a final concentration of 85%, stirred for 2 h, and centrifuged at 8000 Â g for 15 min. The precipitate (fraction 2) was resuspended in deionized water. Both fraction 2 and the supernatant (fraction 3) were dialyzed against water for 2 days (four changes of water). The dialysate (fraction 4) was lyophilized and stored at 2708C. All extraction procedures were conducted at 48C. The antiviral activity of each fraction was determined by plaque reduction assay.
Purification of Stellarmedin A
The fraction containing the antiviral activity (fraction 2) was subjected to column chromatography by using a CM Sepharose column (13 Â 2.6 cm; GE). Equilibration, loading, and washing were carried out in 20 mM sodium phosphate (pH 6.8) and elution was performed with a linear NaCl gradient at a flow rate of 5 ml/min at 48C. After removal of unabsorbed material (fraction 5), the column was eluted consecutively with 0.1 M NaCl (fraction 6), 0.2 M NaCl (fraction 7), and 1.0 M NaCl (fraction 8). The absorbance at 280 nm of each fraction was measured. Each fraction was collected, concentrated, and desalted using 10 kDa ultrafiltration devices (Millipore, Bedford, USA), and tested for anti-HSV-2 activity by using plaque reduction assay.
The active fraction (fraction 6) was dialyzed against water at 48C, adjusted to 20 mM sodium phosphate ( pH 6.8) containing 150 mM NaCl and loaded onto a Superdex 75 column (120 Â 2.0 cm; GE) which was previously equilibrated with same buffer by using a AKTA-fast protein liquid chromatography (FPLC) system (Pharmacia Amersham Biotech, Uppasala, Sweden). The proteins were eluted with an isocratic gradient of 20 mM sodium phosphate ( pH 6.8) containing 150 mM NaCl, at a flow rate of 0.2 ml/min. Each fraction (2 ml) was monitored at 280 nm and analyzed for anti-HSV-2 activity. The active fractions were then pooled, analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The purified antiviral protein exhibited a single band and was designated as Stellarmedin A.
Determination of molecular weight and isoelectric point Stellarmedin A was electrophoresed on a 15% denaturingreducing SDS-PAGE as described previously [20] . The apparent molecular weight of the purified Stellarmedin A was determined by using an FPLC system (TSK-Gel G4000 PWXL column) equilibrated and eluted with 50 mM phosphatebuffered saline (PBS; pH 6.8) at a flow rate of 0.8 ml/min. The isoelectric point (pI) of the purified protein was determined by isoelectric focusing under non-denaturing condition on 5% polyacrylamide gel containing ampholines (pH 8.0-10.5) using the method of Righetti and Chellemi [21] .
Carbohydrate-specific periodic acid schiff staining The staining assay was carried out according to a previously published paper [22] . After SDS-PAGE, the gel was incubated in fixation solution for 2 h and then in periodic solution for another 1 h. After rinsing with water, the gel was incubated in metabisulfite solution for 10 min and then in Schiff's reagent in dark for 3 h. After glycoprotein bands were developed to bright red bands, the gel was washed twice with metabisulfite solution in dark for 1 h and finally washed four times with recovery solution.
Analysis of N-terminal amino acid sequence
The purified Stellarmedin A was electrophoresed and transferred to a polyvinyl fluoride membrane. The band containing the active material was excised from the membrane and sequenced from the amino terminus using the trypsin digestion procedure [23] . The N-terminal sequence was determined by automated Edman degradation using a Procise Protein Sequencer 492 (Applied Biosystems, Carlsbad, USA).
Cytotoxicity evaluation
As a preliminary test of toxicity, replicate wells of uninfected cells were exposed to various concentrations of test substances and incubated for 16 -18 h at 378C. Cell survival rate was measured by using MTT assay as previously described [24] . Cytotoxicity was expressed as 50% of cytotoxic concentration (CC 50 ) at which a substance inhibited up to 50% of cell growth.
Therapeutic effect of Stellarmedin A on HSV infection
To determine anti-HSV activity, Vero cells were grown in 24-well culture plates at 2 Â 10 5 cells/well for 48 h to reach at least 95% confluence. The medium was then discarded and the cell monolayer was infected with 100 plaqueforming units (PFU) of HSV-1 or HSV-2. After an adsorption period of 1 h, the cells were rinsed twice with PBS (pH 7.4) and mixed with media containing different concentrations of Stellarmedin A. The amount of infectious virus was quantified by plaque assay until 48 h post-infection ( p.i.) [25] . Test was carried out in triplicate.
Time-of-addition study
The time-of-addition effect on HSV-2 was examined according to previously described procedures with minor modifications [26] . Briefly, Vero cells were grown in 24-well culture plates at a density of 2 Â 10 5 cells/well for 48 h to reach at least 95% confluence. For pre-infection groups, Stellarmedin A (62.5 mg/ml) was added to plates 6 or 2 h before infection and then cells were washed twice in PBS to eliminate Stellarmedin A and exposed to the virus. 
Peroxidase activity assay
Peroxidase activity assays were carried out as previously described [27] . Guaiacol peroxidase (GPrx) activity was determined and expressed as mmol/min/mg of total protein.
Antiproliferative activity assay
The cytotoxic effect of Stellarmedin A on tumor cells was determined by using MTT staining. Briefly, 5 Â 10 3 cells/ well were plated in 96-well plates with 100 ml of culture medium for 24 h, and then exposed to different concentrations of Stellarmedin A. After 72 h, the culture medium was replaced with 100 ml of fresh medium containing 0.5 mg/ml MTT and incubated for another 4 h at 378C. This medium was then removed, and 100 ml of DMSO was added to each well to dissolve the purple formazan crystals. IC 50 (50% of inhibitory concentration) was calculated by measuring the absorbance at 570 nm with an automatic plate reader (Bio-Tek Instrument Inc., Winooski, USA). Each experiment was repeated three times.
Statistical analysis
Data were expressed as mean + SD of three independent experiments. The Student's t-test was used to analyze data. P , 0.05 was considered to be statistically significant.
Results
Isolation and purification of Stellarmedin A from S. media To investigate the antiviral activity of S. media extracts, a protein designated as Stellarmedin A was isolated from water-soluble fractions of S. media by ammonium sulfate precipitation and column chromatography. As shown in Table 1 , the crude extract (fraction 1) was initially divided into three fractions by ammonium sulfate precipitation. Antiviral activity was predominantly found in the 85% ammonium sulfate precipitate (fraction 2), which was then loaded onto a Sepharose column and further resolved into four fractions. Fraction 6, which displayed the majority of the antiviral activity, was subjected to size-exclusion chromatography (Fig. 1 ) and resolved into a single peak using FPLC system. This fraction was found to possess the maximum (IC 50 ¼ 13.18 mg/ ml) antiviral activity ( Table 2 ) and was resolved as a single band by SDS-PAGE (Fig. 2, lane 1) . This purified antiviral protein was designated as Stellarmedin A.
Identification of Stellarmedin A Carbohydrate-specific periodic acid Schiff (PAS) staining showed that Stellarmedin A was a glycoprotein and the molecular weight of Stellarmedin A was 35116.2 Da (Fig. 2) , suggesting that it was a monomer. The isoelectric focusing pattern showed that the protein migrated towards the cathode end of focused gel and the pI was calculated to be 8.7. The N-terminal sequence of Stellarmedin A, MGNTGVLTGERNDR, was compared with several peroxidase sequences available in SWISS-PROT and NCBIInr databases. Results are listed in Table 3 . It was shown that Stellarmedin A was not identical to any protein published so far. However, it exhibited 64.3% similarity to the N-terminal sequences of peroxidases from other plants.
Cytotoxic effect on viability of Vero cells and anti-HSV activities of Stellarmedin A The cytotoxic activity of Stellarmedin A was investigated by MTT assay. Results showed that Stellarmedin A had no cytotoxic effects at concentrations below 1000 mg/ml. The CC 50 and CC 0 values of Stellarmedin A exceeded 1000 mg/ml ( Table 2) . Therefore, the anti-HSV activity of Stellarmedin A was examined at a concentration of 250 mg/ml or lower.
The inhibitory effect of Stellarmedin A on HSV-1 and HSV-2 was investigated by the plaque reduction assay (Fig. 3) . Results showed that Stellarmedin A inhibited HSV-2 infection in a dose-dependent manner but did not inhibit HSV-1 infection ( Table 2 ). The IC 50 was 13.18 mg/ ml and the therapeutic index (CC 50 /IC 50 ) was .75.9.
To investigate the inhibitory effect of Stellarmedin A on the stage of HSV-2 infection, Stellarmedin A was added at different times of HSV-2 infection. Figure 4 showed that Stellarmedin A effectively inhibited HSV-2 infection with an inhibitory rate .89% when added concurrently. However, the inhibitory rate declined to 32% or lower in 2, 4, and 8 h p.i. groups. In contrast, pre-treatment of cells with Stellarmedin A did not reduce HSV-2 infectivity (Fig. 4) , suggesting that Stellarmedin A affected the initial stage of HSV-2 infection. Peroxidase activity of Stellarmedin A Peroxidase activity was investigated in vitro using the substrate, guaiacol (o-methoxyphenol), which is often used in peroxidase enzyme assays [28] . Peroxidase activity of Stellarmedin A was 36.6 mmol/min/mg protein.
Antiproliferative activity of Stellarmedin A Two human cancer cell lines HL-60 and LoVo and one human normal cell line HFB were used to test the effect of Stellarmedin A on cell proliferation by using MTT assay. Stellarmedin A exerted potent and concentration-dependent cytotoxic effects on HL-60 and LoVo cells with an IC 50 of 9.09 and 12.32 mM, respectively (Fig. 5) . In contrast, Stellarmedin A barely had inhibitory effects on the proliferation of HFB cells.
Discussion
In the present study, an anti-HSV-2 protein, Stellarmedin A, was isolated from S. media. The N-terminus of the protein was used to search SWISS-PROT and NCBIInr databases by using Mascot search engine (http://www.matrixscience.co.
uk) with a tolerance of + 0.1 Da and a missed cleavage site. Five proteins with high similarity were chosen for further analysis ( Table 3) . Acyl-CoA dehydrogenase-like protein (YP_523632.1) shared high similarity with Stellarmedin A (9/14), and the 247th amino acid in its N-terminus matched the 5th amino acid in that of Stellarmedin A. However, the source of this protein is Rhodoferax ferrireducens T118 and the relativeness between two species is too distant. At least four plant peroxidase isozymes (AAC98519.1, AAB41810.1, AAD37427.1, and BAD97439.1) shared 64.3% similarity with Stellarmedin A N-terminus, suggesting that Stellarmedin A was a novel plant protein with peroxidase activity. Subsequently, enzymatic activity assay confirmed that Stellarmedin A had guaiacol peroxidase activity. Peroxidase is involved in many significant processes in plant physiology [29] . As a commercial reagent, peroxidases are often applied in immunohistochemical, enzyme-linked immunosorbent assay (ELISA), and immunoblotting methods. Besides, they have medicinal applications. It has been reported that a 34 kDa peroxidase with antifungal activity against Fusarium solani (IC 50 ¼ 76 mM), Mycosphaerella arachidicola (IC 50 ¼ 103 mM), and Pythium aphanidermatum (IC 50 ¼ 119 mM) is isolated from lima bean seeds [ 30, 31] . French bean legumes produce a 37 kDa peroxidase with inhibitory activity against mycelia growth of Botrytis cinerea, Fusarium oxysporum, and M. arachidicola [32] . However, there is no report showing that this protease has antiviral activity. Stellarmedin A is the first peroxidase with antiviral activity isolated from S. media. A number of antiviral proteins have been described, which can be classified into three groups: ribosomeinactivating proteins (RIP), lectins, and proteins isolated from fungi. RIPs are toxic N-glycosides that inactivate ribosomes and block protein synthesis [33] . Examples of this group include trichosanthin (TCS) which is isolated from Trichosanthes kirilowii and inhibits replication of HIV-1 [34] , and MAP30 from the seeds of Momordica charantia, which exhibits potent anti-HSV and anti-HIV activities [35] . Lectins are defined by their ability of clumping erythrocytes and other types of animal and human cells [36] . Typhonium divaricatum lectin (TDL) is isolated from Typhonium divaricatum [37] and Polygonatum odoratum lectin (POL) from rhizomes of Polygonatum odoratum [11] , both of which have antiviral activity against HSV-2 and antiproliferative effects on human cancer cell lines. The last type comprises proteins isolated from fungi, especially edible mushrooms, such as RC-183 purified from the edible mushroom, Rozites caperata, which was shown to inhibit HSV-1 and HSV-2 replication [25] . GFAHP from Grifola frondosa exhibits antiviral activity against HSV-1 both in vitro and in vivo [38] . In comparison, the lack of identity with any other proteins with known antiviral activity indicated that Stellarmedin A had a novel structure.
The anti-HSV activity assay showed that Stellarmedin A of S. media inhibited HSV-2 but not HSV-1 infection, suggesting some differences between the antiviral profiles of Stellarmedin A from S. media and currently available anti-HSV drugs, most of which have broad-spectrum anti-HSV activity [39] . The effect of addition time on the antiviral activity indicated that the initial stage of HSV-2 infection was inhibited by Stellarmedin A. Currently available anti-HSV drugs mainly inhibit the initial stage of HSV-2 infection by the virus attaching, penetrating cell membrane, and transferring viral DNA into cell nucleus [40] . In addition, treatment of supercoiled plasmid pUC18 revealed that Stellarmedin A exerted DNA-cleavage activity ( Supplementary Fig. S1 ), which might involve in the mechanism of Stellarmedin A antiviral activity. Further studies are required to investigate the detailed mechanism of this activity and to validate the feasibility of developing Stellarmedin A as an anti-HSV agent. 
